12V 주식 개요 는 미국 및 전 세계에서 진단 회사로 운영되고 있습니다. 자세한 내용
보상 위험 분석 위험 검사에서 12V 에 대한 위험이 감지되지 않았습니다.
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Veracyte 과거 주가 현재 주가 US$44.60 52주 최고치 US$44.60 52주 최저치 US$17.50 베타 1.71 1개월 변경 13.20% 3개월 변경 사항 42.04% 1년 변경 사항 92.24% 3년 변화 85.83% 5년 변화 85.83% IPO 이후 변화 437.35%
최근 뉴스 및 업데이트
Third quarter 2024 earnings released: EPS: US$0.20 (vs US$0.41 loss in 3Q 2023) Nov 08
Veracyte, Inc. Raises Earnings Guidance for the Full Year 2024 Nov 07
Veracyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 17
Veracyte, Inc. Presented New Data At Astro 2024 Show That Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men Oct 02
Veracyte, Inc. Announces New Data from a Phase 3 Trial of the Multi-Center, Randomized Stampede Clinical Trial Sep 16
Veracyte, Inc. Announces New Board Appointments Sep 05 더 많은 업데이트 보기
Third quarter 2024 earnings released: EPS: US$0.20 (vs US$0.41 loss in 3Q 2023) Nov 08
Veracyte, Inc. Raises Earnings Guidance for the Full Year 2024 Nov 07
Veracyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 17
Veracyte, Inc. Presented New Data At Astro 2024 Show That Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men Oct 02
Veracyte, Inc. Announces New Data from a Phase 3 Trial of the Multi-Center, Randomized Stampede Clinical Trial Sep 16
Veracyte, Inc. Announces New Board Appointments Sep 05
Forecast breakeven date moved forward to 2024 Aug 08
New minor risk - Share price stability Aug 08
Second quarter 2024 earnings released: EPS: US$0.075 (vs US$0.12 loss in 2Q 2023) Aug 07
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024 Aug 07
Veracyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 18
Insufficient new directors Jul 01
Veracyte, Inc. Announces New Afirma Grid Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors Jun 05
New major risk - Revenue and earnings growth May 09
Forecast to breakeven in 2025 May 09
First quarter 2024 earnings released: US$0.025 loss per share (vs US$0.11 loss in 1Q 2023) May 08
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2024 May 08
Veracyte, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Veracyte, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 23
New minor risk - Shareholder dilution Mar 02
New minor risk - Profitability Feb 26
Full year 2023 earnings released: US$1.02 loss per share (vs US$0.51 loss in FY 2022) Feb 23
Veracyte, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 23
Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors Feb 16
Veracyte, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 09
Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of C2i Genomics, Inc. Feb 06 Veracyte, Inc. (NasdaqGM:VCYT) has reached a definitive agreement to acquire C2i Genomics, Inc. for $95 million.
New minor risk - Share price stability Nov 10
Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.12 loss in 3Q 2022) Nov 10
Veracyte, Inc. Reports Consolidated Impairment Charges for the Quarter Ended September 30, 2023 Nov 09 Veracyte, Inc. Raises Revenue Guidance for the Full Year 2023
Veracyte, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 18
Veracyte, Inc. Announces New Data from A Large, Randomized Phase 3 Trial Reinforce the Value of the Decipher Prostate Genomic Classifier in Helping Physicians Make More Informed Treatment Decisions for Their Patients with Prostate Cancer Oct 05
Veracyte, Inc. Announces New Data Presented At the 2023 American Thyroid Association Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer Sep 29
Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023 Sep 28
Veracyte, Inc. Announces Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer Aug 23
Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023 Aug 11
Veracyte, Inc. Revises Revenue Guidance for the Full Year 2023 Aug 10
Second quarter 2023 earnings released: US$0.12 loss per share (vs US$0.13 loss in 2Q 2022) Aug 09
Veracyte, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 22
Veracyte, Inc. Announces New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer Jun 21
Veracyte Announces That New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer May 13
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.20 loss in 1Q 2022) May 07
Veracyte, Inc. Raises Earnings Guidance for the Full-Year 2023 May 06
Full year 2022 earnings released: US$0.51 loss per share (vs US$1.11 loss in FY 2021) Feb 24
Veracyte, Inc. Announces New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment Feb 14
Veracyte, Inc. to Report Q4, 2022 Results on Feb 22, 2023 Feb 07
Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer Dec 15
Independent Director recently sold €176k worth of stock Nov 17
Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.20 loss in 3Q 2021) Nov 04
Veracyte, Inc. Raises Revenue Guidance for the Year 2022 Nov 03
Veracyte, Inc. Announces New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy Oct 27
Veracyte, Inc. Announces Data That Provide New Insights into Thyroid Tumor Behavior Oct 25
New Data Presented At American College of Chest Physicians 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer Oct 19
Veracyte, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 14
Veracyte, Inc. Publishes New Data in JNCI Demonstrate its Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men Sep 23
Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmonology & Market Access Sep 14
Veracyte, Inc. Announces That New Data from a Phase 3 Trial of the Multi-Center, Multi-National, Randomized Stampede Platform Protocol Sep 12
Veracyte, Inc. Announces New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for Car T-Cell Therapy in Patients with Large B-Cell Lymphoma Aug 30
Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors Aug 12
Co-Founder & Executive Chairwoman recently sold €3.3m worth of stock Aug 11
Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2021) Aug 03
Veracyte, Inc. Revises Revenue Guidance for the Year 2022 Aug 03
Veracyte, Inc. Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid Jul 21
Veracyte, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 15
Veracyte, Inc. Announces New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis Jul 14 Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice Jun 21
CEO & Director recently bought €931k worth of stock Jun 14
Veracyte, Inc. Announces the Publication of Data Reinforcing the Clinical Utility of the Decipher Prostate Genomic Classifier Jun 04
Veracyte, Inc. Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer Jun 01
Veracyte, Inc. Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors May 27
Veracyte, Inc. Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment May 17
First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.66 loss in 1Q 2021) May 05
Veracyte, Inc. Revises Revenue Guidance for the Full Year 2022 May 04
Veracyte, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 20
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Veracyte, Inc. Provides Revenue Guidance for the Full Year 2022 Mar 02
Veracyte, Inc. Appoints Annie Mcguire as Senior Vice President and General Counsel Mar 01
Veracyte, Inc Appoints Jonathan Wygant as Chief Accounting Officer Feb 24
Veracyte, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 16
Veracyte, Inc. Announces New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier Feb 15
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis Dec 15
Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.075 loss in 3Q 2020) Nov 10
Veracyte, Inc Announces New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy Sep 15
Executive VP, General Counsel & Secretary James Erlinger has left the company Aug 05
Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.22 loss in 2Q 2020) Jul 30 Veracyte, Inc.(NasdaqGM:VCYT) dropped from Russell 3000 Growth Index
Veracyte, Inc. Publishes New Data in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer Jun 15
Independent Director Fred Cohen has left the company Jun 11
Veracyte, Inc. Receives Final Medicare Coverage Policies for Decipher Bladder Jun 05
Independent Director recently bought €58k worth of stock Jun 05
Veracyte, Inc. (NasdaqGM:VCYT) entered into a memorandum of understanding to acquire HalioDx SAS from M.I.3. SA, PSIM fund managed by Bpifrance Investissement SAS, Sham Innovation Santé advised by Turenne Capital, Bpifrance Investissement SAS, Sofipaca SCR, Amundi Private Equity Funds S.A., Quest for Growth Belgium (ENXTBR:QFG) managed by Capricorn Venture Partners and others for approximately €260 million. Jun 02
Veracyte, Inc. Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples May 27
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier May 26 주주 수익률 12V DE Biotechs DE 마켓 7D 6.2% 1.0% 1.9% 1Y 92.2% -4.3% 15.1%
전체 주주 수익률 보기
수익률 대 산업: 12V 지난 1년 동안 -4.3 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: 12V 지난 1년 동안 15.1 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is 12V's price volatile compared to industry and market? 12V volatility 12V Average Weekly Movement 6.3% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: 12V 지난 3개월 동안 German 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: 12V 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 는 미국 및 전 세계에서 진단 회사로 운영되고 있습니다. 이 회사는 암성 갑상선 결절 진단을 위한 Afirma Genomic Sequencing Classifier, 전립선암 진단을 위한 Decipher Prostate Biopsy 및 근치적 전립선 절제술, 유방암 진단을 위한 Prosigna Breast Cancer Assay, 폐암 진단을 위한 Percepta Nasal Swab Test, 특발성 폐섬유증을 포함한 간질성 폐질환 진단을 위한 Envisia Genomic Classifier를 제공하고 있습니다. 또한 엔비시아 클래시파이어, 엔카운터 분석 시스템, 림프종 아형 검사에 사용되는 림프마크도 개발하고 있습니다.
자세히 보기 Veracyte, Inc. 기본 사항 요약 Veracyte 의 수익과 매출은 시가총액과 어떻게 비교하나요? 12V 기본 통계 시가총액 €3.40b 수익(TTM ) -€8.94m 수익(TTM ) €410.32m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 12V 손익 계산서(TTM ) 수익 US$425.33m 수익 비용 US$128.38m 총 이익 US$296.96m 기타 비용 US$306.22m 수익 -US$9.27m
주당 순이익(EPS) -0.12 총 마진 69.82% 순이익 마진 -2.18% 부채/자본 비율 0%
12V 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/02 13:41 장 마감 주가 2025/01/31 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Veracyte, Inc. 18 애널리스트 중 11 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Sung Ji Nam BTIG Bryan Brokmeier Cantor Fitzgerald & Co. Matthew Sykes Goldman Sachs
15 더 많은 분석가 보기 
